TGA Device Reporting And Supply Readiness

Learning objectives

• Explain the staged TGA reporting obligations that began for healthcare facilities on 21 March 2026.
• Identify the device-event details perfusion and theatre teams should preserve before a local investigation is complete.
• Build a practical readiness checklist that links clinical incident reporting, device traceability, and procurement escalation.

Key takeaways

• Since 21 March 2026, Australian public, private, and day hospital facilities must report death, serious injury, or serious deterioration associated with high-risk medical devices.
• Near misses and treatment-related incidents become mandatory in later stages, but teams can start capturing them now because the workflow is the same at the bedside.
• For perfusion services, readiness means linking incident capture, device identifiers, UDI where available, batch or serial data, and supply-risk escalation into one routine.

Why this matters for perfusion

Perfusion teams work with devices where safety and supply are tightly coupled: oxygenators, centrifugal and roller pump systems, reservoirs, cannulae, cardioplegia delivery sets, heater-cooler interfaces, ECMO circuitry, disposables, and software-supported monitors. A fault, unexpected performance pattern, or shortage can move from operational inconvenience to patient risk quickly.

The Therapeutic Goods Administration is shifting healthcare facilities from optional reporting habits toward a more formal signal-detection model. That matters because a local event that feels isolated may be one of the first visible signals of a broader device problem.

What changes from March 2026

The first mandatory stage began on 21 March 2026. In Stage 1, healthcare facilities must report adverse events that result in death, serious injury, or serious deterioration when they are associated with high-risk medical devices. The TGA describes high-risk devices for this stage as Class III medical devices and Class 4 in vitro diagnostic devices.

This is not yet the final reporting state. The mandatory scope widens on 1 April 2028 to include medium-risk devices and near adverse events, then widens again on 1 April 2030 to include treatment provided for serious injury or serious deterioration involving the relevant device classes. The safer operational choice is to build the capture workflow now, not rebuild it with each stage.

• 21 March 2025 to 20 March 2026: voluntary reporting period for facilities to build capability.
• 21 March 2026: Stage 1 starts with serious outcomes associated with high-risk devices.
• 1 April 2028: Stage 2 expands mandatory reporting to medium-risk devices and near adverse events.
• 1 April 2030: Stage 3 expands to treatment-related reporting for serious injury or deterioration.

Do not wait for certainty

The practical threshold is suspicion, not proof. The TGA guidance says reporting does not require certainty that the device caused the event and does not require a completed investigation before reporting. That is a major cultural point for clinical teams.

In perfusion practice, that means a suspected oxygenator performance problem, unexplained circuit component failure, cannula or line defect, heater-cooler interface issue, monitoring software problem, or disposable failure should be captured while the details are still fresh. The later investigation can refine the story; it cannot recreate missing identifiers or timing data after the fact.

The deadline should drive the workflow

The Stage 1 reporting clock is short. Reports about device-related adverse events resulting in death or serious deterioration must be submitted within 10 days from the day of death or the day the serious deterioration was first identified in the facility.

From Stage 2, near misses and treatment-related incidents have a 45-day reporting timeframe. That longer window should not make near misses feel casual. A near miss is often the cleanest chance to find a fragile device process before the next patient is exposed.

• Escalate serious device-event suspicion on the day it is identified.
• Record who owns the report, who holds device details, and which centralised health department or private group pathway applies.
• Use IRIS for urgent or unusual voluntary reports when needed, but avoid duplicate mandatory reports if the event has already been reported through an accepted pathway.
• Keep evidence that shows when the event was identified and when the report was submitted.

What to capture at the bedside

The reporting system cannot do useful signal detection if the source data is vague. At minimum, teams should capture the facility identifier, date of use, device description, incident description, and manufacturer if known. In practice, perfusion services should go further whenever possible.

A strong local record should make the device traceable. That means trade name, model, lot or batch number, serial number, pump or console identifier, software version if relevant, expiry date, sterilisation or packaging abnormality, and Unique Device Identifier data when available. It should also record what happened clinically, what was changed in the circuit or treatment plan, and what follow-up action occurred.

• Device name, model, manufacturer, lot or batch, serial number, and UDI if available.
• Clinical outcome: death, serious deterioration, serious injury, temporary harm, minor harm, or no harm near miss.
• Event timing: date of use, date deterioration was identified, date of death if applicable, and date of intervention for near misses.
• Operational response: device quarantine, replacement, sponsor contact, biomedical engineering review, procurement alert, and TGA pathway used.

Make responsibility explicit

The facility chief executive officer or equivalent carries the statutory responsibility, but the working system needs named operational owners. A perfusion event can involve theatre, ICU, biomedical engineering, procurement, risk, quality, and the supplier. If ownership is vague, the reporting window will be consumed by handoffs.

A useful local rule is simple: the clinical team preserves facts, the nominated risk or quality lead manages the TGA pathway, biomedical engineering and procurement preserve device and supply evidence, and the department lead confirms that the loop closed. This is not about blame. It is about making the reporting pathway faster than the rate at which details disappear.

Supply risk is part of patient safety

The second readiness problem is supply. The TGA now has a more visible medical-device supply-disruption pathway, and section 41HD approvals can allow nominated medical devices to be imported and supplied during supply emergency situations when substitutes are unavailable, in short supply, or likely to become short supply, and when public health needs justify it.

That does not help the bedside team if procurement only learns about fragility after stock has already failed. Perfusion services should maintain a short list of clinically critical devices where substitution is difficult: oxygenators, tubing packs, arterial filters, cannulae, cardioplegia components, ECMO disposables, heater-cooler interfaces, and any single-supplier components in local protocols.

• Identify devices where there is no clinically comfortable substitute.
• Track supplier lead times, backorder signals, recalls, discontinuations, and global alerts.
• Agree who can approve substitute evaluation, staff education, and protocol changes before stock reaches a critical level.
• Keep supply-risk notes connected to clinical risk registers rather than buried only in purchasing email threads.

Readiness checklist

A good readiness check is practical enough to use in a department meeting. It should test whether a serious device signal can move from the pump, theatre, ICU, or procurement desk into the right reporting and supply-risk pathway without waiting for one person to remember the process.

• Staff can recognise death, serious injury, serious deterioration, near miss, and treatment-related device events.
• Local incident forms include device identifiers, UDI where available, event timing, clinical outcome, and follow-up action.
• A named reporting lead knows the ASDER registration pathway and when IRIS is appropriate for urgent or unusual events.
• Biomedical engineering and procurement know how to preserve device evidence and contact suppliers without losing the clinical timeline.
• High-risk and hard-to-substitute devices have a supply escalation plan before a shortage reaches the bedside.

The practice change

The main change is not a new form. It is a new expectation that device safety and device supply risks are visible early enough for action. For perfusion teams, the practical move is to treat device-event documentation as part of clinical safety work, not administrative cleanup after the case.

If your department can identify the event, preserve the device details, notify the right lead, and escalate supply fragility before the next patient is affected, the regulatory change has become useful rather than merely burdensome.

References

1. Reporting of medical device adverse events by healthcare facilities
2. Obligations to report an adverse event for medical devices
3. Medical device supply disruptions
4. About section 41HD approvals for import and supply